Afleveringen
-
In the third episode of Season 3, we spoke with Dr. James Min, Founder and CEO of Cleerly Health, about his experience turning his clinical research into Cleerly and how he’s managed the business as the treatment of coronary artery disease evolves thanks to new research, new technology like generative AI, or new business models like value-based care reimbursement. Our discuss touches on processes to utilize to ensure product market fit, how firms should think about building healthcare AI products, and the importance of challenging dogma.
-
In the second episode of Season 3, we spoke with Dr. Barthalomew Sillah, COO of Avesta76 therapeutics about his experiences turning innovative science into impactful therapeutics. Our conversation touched on being open-minded to new opportunities, learning from non-biotech experiences in the healthcare ecosystem, and championing inclusion in the industry.
-
Zijn er afleveringen die ontbreken?
-
In the first episode of Season 3 of LifeSci Beat, we chatted with Eshwar Inapuri, Former CEO & Co-Founder of InnaMed. Our conversation spanned diagnostics company creation, navigating challenges as a young entrepreneur, and new frontiers and trends in the diagnostics space.
InnaMed is an at-home blood testing company focused on improving the monitoring and treatment of patients undergoing heart failure, kidney transplant, hypoparathyroidism and in vitro fertilization. InnaMed was acquired by Fluxergy in 2023.
-
In this episode, we chatted with Dr. James Mutamba, CBO of Arrakis Therapeutics. Our conversation covered biotech IPO financing, the process of business development dealmaking, company creation, and the Arrakis Therapeutics platform. Arrakis Therapeutics is an preclinical private biotech developing RNA-targeted small molecules. They combine insights into RNA structure, chemistry, and biology to pioneer a new class of medicines focused on oncology and genetically validated diseases.
-
In this ninth episode, we spoke with Oriana Papin-Zoghbi, co-founder and CEO of AOA Dx. We discussed her global upbringing and early career, the current standard of ovarian cancer diagnosis, and building a company from academic research.
-
In the eighth episode of this season, we chatted with Alex Sapir about his various experiences leading life sciences companies through commercial launches and key funding milestones. We spoke about his career beginnings at GSK, ZS Associates, and United Therapeutics. Additionally, we covered his CEO tenures at Dova Pharmaceuticals and ReViral Ltd - both of which were acquired.
-
In this episode, we sat down with Geoff Meyerson — CEO & Co-Founder at Locust Walk. We discuss Geoff’s extensive life science career, which includes stints in investment banking, venture capital, and business development. We also dive into the founding story and journey of Locust Walk, a global investment bank that integrates corporate development strategy and execution with capital raising for innovative life science companies, and hear Geoff’s outlook on the year ahead for biotech.
-
In the sixth episode of our second season, we sat down with Dr. Pitamber "Pitou" Devgon, co-founder of Velano Vascular, active angel investor, and Lecturer at the Wharton School of Business. We discussed the origins of Velano Vascular’s central PIVO™ technology, the importance of collecting insightful data to de-risk early ventures, innovation through acquisition, and much more.
Founded in 2012, Velano Vascular set out to transform the patient experience with PIVO™, a needle-free blood collection device. After inventing this breakthrough technology, Pitou led Velano Vascular's growth through eventual acquisition by BD in 2021.
-
In this episode, we chatted with Dr. Imogen Pryce, COO of R&D at Relay Therapeutics. Our conversation covered Relay Therapeutics’ scientific strategy, its unique Dynamo™ platform, and its underlying commercialization strategy and scientific differentiation.
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company that integrates disparate technologies to push drug discovery. Specifically, its Dynamo™ platform integrates leading-edge computational and experimental approaches designed to drug previously-intractable protein targets.
-
In the fourth episode of our second season, we spoke with Rami Elghandour, Chairman & CEO of Arcellx. Our conversation focused on the importance of building a company's culture from day one and how firms can turn their cultures into a competitive advantage.
Arcellx is a clinical stage biotech company reimagining cell therapy. The company recently announced a strategic collaboration with Kite.
-
In the third episode of our second season, we spoke with Dr. Ankit Mahadevia, CEO of Spero Therapeutics and former Venture Partner at Atlas Venture. Our conversation focused on the benefits of diverse exposure within the healthcare ecosystem, unique challenges of developing antibiotics, and leadership lessons learned through a prolonged career company creation.
Spero Therapeutics is a public company focused on developing next-generation antibiotics for infectious diseases based in Cambridge, MA.
-
On the second episode of this season, we chatted with Leo Grady Ph.D. Our conversation focused on his career working at medical technology companies and the many applications of AI in healthcare. Leo is internationally recognized for his work to deliver AI in healthcare for 20 years at the multinational medical company Siemens and pioneering startups HeartFlow and Paige.AI. As CEO of Paige, Leo led the company to become an industry leader, internationally launching groundbreaking products and receiving the first-ever FDA approval for an AI product in pathology. Leo is currently CEO in Residence with Breyer Capital and Founder and CEO of Jona.
-
In the first episode of our second season, we chatted with Dr. Kiersten Stead, Managing Partner at DCVC Bio. Our conversation focused on computational drug discovery, her latest investments, and the keys to company creation in this burgeoning space.
DCVC Bio is the bio-focused arm of DCVC, a VC with $3B+ in AUM focused on deep-tech investing, where Kiersten invests in therapeutics, agriculture, and synthetic biology companies with a deep-tech advantage.
-
In our final episode of our first season, we chatted with John Evans, CEO of Beam Therapeutics. Our conversation spans lessons in commercializing therapies across the development life cycle, programmable gene editing platforms, evaluating biopharma partnerships, future trends in gene therapy accessibility, and more.
Beam Therapeutics is a leader in the nascent gene editing space, pioneering proprietary base editing to develop precision genetic medicines. In January 2022, Beam entered a $300M+ research collaboration with Pfizer. Beam Therapeutics is based in Cambridge, MA.
-
In this episode, we spoke with Brian Harris, CEO and Co-Founder of MedRhythms. We explore Brian’s upbringing and how his passion for music and desire to help people manifested into the career he has today. We dive into his career as a music therapist which led to the creation of MedRhythms. MedRhythms uses sensors, music, and software to build digital therapeutics that aim to improve walking impairments caused by neurologic injuries. MedRhythms raised their series B last year and is featured as one of CBInsights top 150 most innovative digital health companies.
Music Featured: Walk This Way by Aerosmith
-
In this episode, we sat down with Dr. Enoch Kariuki – former CEO at Lengo Therapeutics, CFO at VelosBio, and SVP of Corporate Development at Synthorx. We explore Enoch’s upbringing in Kenya and how a family member’s battle with HIV inspired his pursuit of a career in healthcare. We also dive into Enoch’s journey as a biotech executive at three separate start-ups, all of which were acquired. Enoch is based in San Diego, CA.
-
In this episode, we sat down with Dr. Osvaldo (Lalo) Flores, CEO at Century Therapeutics. We discuss Lalo's early career in R&D, the founding story (and eventual acquisition) of Novira Therapeutics, and his outlook on next-generation cell therapies with Century.
Century Therapeutics is a biotechnology company developing transformative allogeneic cell therapies to create products for both hematological and solid tumor malignancies. In January 2022, Century entered into a strategic collaboration with Bristol Myers Squibb (BMS) to develop induced pluripotent stem cell (IPSC)-derived allogeneic cell therapies. Century is based in Philadelphia, PA.
-
In this episode, we sat down with Dr. Ali Behbahani, General Partner at New Enterprise Associates. Dr. Behbahani has been with NEA since 2007, spearheading over 40 biotech and medtech investments such as CRISPR Therapeutics, Adaptimmune, and Nevro. We discussed his views on breaking into VC, his approach to assessing early-stage life science innovations, the current trends in the biotech investing landscape, and much more.
NEA is a global VC firm with $25B in AUM and over 300 active investments across both technology and healthcare sectors. Founded in 1977, NEA has made transformational investments such as Robinhood, Salesforce, Bright Health, and CRISPR Therapeutics. NEA has offices in Menlo Park, San Francisco, New York, and the Washington, D.C. metro area, and is widely considered one of the largest leading VCs in the world.
-
In this episode, we sat down with Karun Naga, Partner at The Foundry, a leading venture studio focused on building pioneering life-saving medical technologies. We discuss the business model of The Foundry, Karun's early career journey that led him to medical device start-ups, his successful start-ups and the acquisition process, and much more.
The Foundry is a team of entrepreneurs committed to inventing technologies and building companies that redefine the standard of care and transform patients’ lives. The Foundry’s 20+ companies have raised nearly $1 Billion from over 50 venture capitalists and corporations, creating more than $3 Billion in shareholder value.
While at The Foundry, Karun and his team built a catheter-based treatment for hypertension that was later acquired by Medtronic. His more recent endeavor was leading the incubation efforts and being the CEO of Allay Therapeutics, a post-surgical pain management solution that eliminates the need for opioids. Allay Therapeutics closed a Series C round of funding for $60 million in 2021.
-
In this episode, we chatted with Molly Gibson, Co-Founder of Generate Biomedicines, a biotech that uses AI/ML to generate protein medicines and recently closed a $370M Series B financing. We discussed the key trends in computationally-powered drug discovery and bioplatforms, what it takes to commercialize early-stage biotechnology, and much more.
Founded in 2018 under the Flagship Pioneering ecosystem, Generate Biomedicines leverages machine intelligence to computationally generate de-novo (i.e., does-not-exist-in-nature) protein therapeutics.
- Laat meer zien
